Meridian Clinical Research, a clinical investigational site, has taken the COVID-19 pandemic head on, conducting clinical trials in Nebraska (Norfolk and Omaha) and South Dakota (Dakota Dunes). The medical clinical seeks to support the sponsors in determine the safety and efficacy of investigational vaccines intended to protect against SARS-CoV-2, the coronavirus behind the COVID-19 pandemic.
The study sites include:
Who is Meridian Clinical Research?
Based in Omaha, Nebraska, Meridian Clinical Research recently acquired the assets and operations of Regional Clinical Research, Inc. in what was, prior to the COVID-19 pandemic, ongoing consolidation among privately-held clinical investigational site operations. These acquisitions were in response to what is a largely fragmented clinical research site marketplace.
By absorbing Regional Clinical Research, Meridian picked up four research sites in the southern area of New York and the firm now has 20 clinical investigational sites. Both commercial research sites are members of the Platinum Research Network. Founded in 1999, Meridian Clinical Research starts to expand its site footprint with locations in the Midwest/Plains States, New York State, Maryland, Georgia, Virginia and Louisiana.
According to their website, they have enrolled over 42,000 subjects and conducted 2,400 clinical trials since 1999. These figures are significant—they mean that this firm is able to conduct about 114 clinical trials per year, which is significant for a firm that TrialSite News estimates to employ just under 100. Of course, these numbers are based on the combination of a number of firms.
Call to Action: If you are based in Nebraska or South Dakota near these sites and seek to contribute to the development of a COVID-19 vaccine, consider learning more.